Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Integrating new evidence into clinical practice ensures that patients benefit from the most recent advancements in diabetes treatment, improving outcomes and quality of life
Astaxanthin has poor water solubility, a high melting point, low bioavailability, and is vulnerable to chemical breakdown under conditions such as an acidic environment and exposure to heat, light, and oxygen
Therefore, rat GGT may provide insight into human GGT expression and regulation
Preserving physiologic release of GH even while influencing the maximum concentration of the hormone in the bloodstream is critical to ensuring enhanced effects without increased side effects
Heres what I found: Bariatric surgery leads to greater, more durable weight loss and comorbidity reduction compared to GLP-1s GLP-1s offer substantial but less sustained comorbidity benefit with higher discontinuation rates (up to 50% at 35 yrs) GLP-1s do not eliminate the need for bariatric surgery in severe obesity Total weight loss trends higher for bariatric surgery, and real-world GLP-1 effectiveness is generally lower than clinical trial results (a significant finding that deserves its own post) Bariatric surgery is generally more effective than GLP-1s for long-term diabetes remission and cardiovascular risk reduction GLP-1s are associated with higher ongoing costs and are less cost-effective than bariatric surgery long-term The take home: GLP-1s are a valuable addition but dont replace bariatric procedures for patients with severe obesity or those requiring durable, substantial weight loss with co-morbidity reduction
The FeS-binding proteins mitoNEET (also known as CISD1) and NAF1 (also known as CISD2), which have been shown to participate in mitochondrial iron transport, inhibit ferroptosis by protecting mitochondria from lipid peroxidation in cancer cells and acute kidney injury [52, 53]
